Paul Chan: HKEX will consult the market on the specific implementation plan for promoting the "T+1" settlement cycle in the first half of the year
Paul Chan, Secretary for Finance of the Hong Kong Special Administrative Region Government, stated that to continuously optimize the securities market, attract issuers, and enhance market efficiency, the HKEX will advance the following initiatives:In the first quarter, consult the market on revising listing requirements for companies with “different voting rights,” facilitating secondary listings by overseas issuers, streamlining the initial public offering (IPO) process, and providing greater flexibility for biotechnology and specialized technology companies applying for listing; in the first half of the year, implement improvements to the listing framework for structured products and consult the market on specific implementation plans for promoting a “T+1” settlement cycle;Reform the standard trading lot size in the securities market and, in collaboration with the Hong Kong Securities and Futures Commission and the industry, launch a paperless securities market system within the year.
Source:富途快讯 · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
Billionaire investor Chase Coleman’s Tiger Global fund disclosed in its latest 13F filing that its top five growth stocks are all focused on AI infrastructure, including TSMC, NVIDIA, Amazon, Meta, and Google.
-
2
Will the BEAM token go to zero? Could it rise to $1,000? An in-depth analysis of the Beam network and its market prospects
-
3
What Is CVP? An In-Depth Analysis of the PowerPool Ecosystem and the Investment Value of Its Token, CVP
-
4
Analysis of CRYSTAL’s Value and Investment Potential: An Examination of Multiple Projects and Risk Assessment
-
5
Analysis: The State Street Healthcare ETF (XLV) has an expense ratio of 0.08% and a diversified portfolio, while the Invesco Biotechnology ETF (PBE) has an expense ratio of 0.58% and focuses on small-cap stocks; PBE is up 10.2% year-to-date, outperforming XLV.
-
6
Ethereum Recent Rebound: Price Breaks Above $1,970, but Multiple Risks Remain
-
7
QUARTZ Coin Analysis: An Overview of the Sandclock (QUARTZ) and Unique Network’s Quartz (QTZ) Projects
-
8
What Is JGN? Analysis of the JGN (Sword Saint Coin) Project’s Positioning, Features, and Value
-
9
Iran-linked exchange Shelbit allegedly sent $676 million to Binance in sanctions-evasion operation, Reuters reports
-
10
NVIDIA and AMD: The Two Giants of AI Computing Power in 2026—An Analysis of Market Dynamics, Financial Performance, and Opportunities for Transition into Cryptocurrency Mining
Markets Today
Recommended Reading









